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Treatment of rheumatoid arthritis (RA) has dramatically changed
over the past decade, and much progress has been made in
improving the prognosis of RA patients as a result of elaboration
of novel treatment strategies and the development of biologic
agents. Nevertheless, up to 50% of patients are either not
controlled sufficiently or do not respond at all to current
treatments, including biologicals. A better understanding of the
background of these therapeutic limitations is required, but
novel therapies that might help to reduce the residual and
significant burden of the disease also represent future hopes.
RA is an autoimmune disease characterized by inflammation
of the synovial membrane affecting cartilage and bone, which
leads to joint destruction, disability and premature mortality.
Given the therapeutic deficiencies that still exist, it is
mandatory that we conduct further research to close the gap
and find alternative therapies for RA patients. Currently, there
exist several new molecules for the treatment of RA, aimed at
different targets. They may soon become available to RA
patients. These include a monoclonal antibody that targets
inhibition of B cells and a fusion protein that is a T cell
costimulation modulator (inhibiting the activity of T cells).
Another promising approach currently being developed is
inhibition of IL-6 by blockade of both its membrane and
soluble receptors. This approach is based on extensive
research into the biology of and response to IL-6, and into the
effects of IL-6 on target organs expressing the IL-6 receptor
or organs that become sensitive to IL-6 when the
concentration of either IL-6 or of its soluble receptor increase.
The well characterized joint and bone alterations that occur in
RA appear to be partly linked to the effects of IL-6, as are
many of the systemic signs of the disease. This observation
has been confirmed in animal models of RA, and initial
studies of IL-6 blockade have shown that blocking the effects
of IL-6 improves adult RA and other autoimmune diseases in
which IL-6 may be involved.
The papers included in this supplement describe in greater
detail research into IL-6 activity as a potential target for
therapeutic intervention in RA patients. They also describe
the rationale for bringing IL-6 receptor inhibition from the
bench to the bedside.
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